Praxis Biologics Inc said itbegan its initial public common stock offering of 1,750,000shares at 15.50 dlrs a share.    The company said proceeds of the offering will be used tofund product research and development, including clinicaltesting.    It said the money will also be used to cover acquisition,construction and equipment costs and for working capital.    The offering is being managed by Shearson Lehman Bros Incand Merrill Lynch Capital Markets, the company said. Reuter&#3;